Experienced in Subacute Combined Degeneration

Dr. Stephen M. Schleicher

Oncology | Hematology Oncology | Hematology
Rhea Medical Center
9400 Rhea County Hwy, 
Dayton, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Subacute Combined Degeneration
Rhea Medical Center
9400 Rhea County Hwy, 
Dayton, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Stephen Schleicher is an Oncologist and a Hematologist Oncology provider in Dayton, Tennessee. Dr. Schleicher is rated as an Experienced provider by MediFind in the treatment of Subacute Combined Degeneration. His top areas of expertise are Familial Colorectal Cancer, Lynch Syndrome, Colorectal Cancer, and Iron Deficiency Anemia. Dr. Schleicher is currently accepting new patients.

His clinical research consists of co-authoring 42 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in MA
Hospital Affiliations
Tristar Summit Medical Center
Rhea Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
US Health and Life
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

RHEA MEDICAL CENTER
9400 Rhea County Hwy, Dayton, TN 37321
Other Locations
TENNESSEE ONCOLOGY PLLC
2004 Hayes St, Suite 350, Nashville, TN 37203

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Single Treatment Pharmacokinetic and Safety Study of Natroba (Spinosad) Topical Suspension 0.9% w/w in Subjects 1 Month to 3 Years 11 Months of Age With an Active Scabies Infestation
A Single Treatment Pharmacokinetic and Safety Study of Natroba (Spinosad) Topical Suspension 0.9% w/w in Subjects 1 Month to 3 Years 11 Months of Age With an Active Scabies Infestation
Enrollment Status: Recruiting
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 4
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks.
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo Controlled Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks.
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: LY3471851
Study Phase: Phase 1
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: NKTR-358
Study Phase: Phase 1
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2 Dose-Response Study to Determine Safety and Effectiveness of Two Concentrations of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies
A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies
Enrollment Status: Completed
Publish Date: May 21, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

42 Total Publications

Pilomatrical Carcinoma: A Case Report and Review of the Literature.
Pilomatrical Carcinoma: A Case Report and Review of the Literature.
Journal: International journal of dermatology
Published: April 29, 2025
Similar Doctors
Distinguished in Subacute Combined Degeneration
Dr. Jennifer L. Jones
Hematology Oncology | Hematology | Oncology
Distinguished in Subacute Combined Degeneration
Dr. Jennifer L. Jones
Hematology Oncology | Hematology | Oncology

Nsh Cancer Institute Professional Services G LLC

101 Riverstone Vis, Suite 102, 
Blue Ridge, GA 
 (59.2 miles away)
706-258-4140
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Jones is a Hematologist Oncology specialist and a Hematologist in Blue Ridge, Georgia. Dr. Jones is rated as a Distinguished provider by MediFind in the treatment of Subacute Combined Degeneration. Her top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Paget Disease of the Breast, Pancreatectomy, and Hepatectomy. Dr. Jones is currently accepting new patients.

Distinguished in Subacute Combined Degeneration
Dr. Thomas B. Repine
Hematology Oncology | Hematology | Oncology
Distinguished in Subacute Combined Degeneration
Dr. Thomas B. Repine
Hematology Oncology | Hematology | Oncology

Thompson Oncology Group

9711 Sherrill Blvd, 
Knoxville, TN 
 (55.8 miles away)
865-374-3901
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Thomas Repine is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Repine is rated as a Distinguished provider by MediFind in the treatment of Subacute Combined Degeneration. His top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Inflammatory Breast Cancer, and Familial Colorectal Cancer. Dr. Repine is currently accepting new patients.

Distinguished in Subacute Combined Degeneration
Dr. Ross E. Kerns
Hematology Oncology | Hematology | Oncology
Distinguished in Subacute Combined Degeneration
Dr. Ross E. Kerns
Hematology Oncology | Hematology | Oncology

Tennessee Cancer Specialists PLLC

9957 Sherrill Blvd, 
Knoxville, TN 
 (55.2 miles away)
865-693-2244
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ross Kerns is a Hematologist Oncology specialist and a Hematologist in Knoxville, Tennessee. Dr. Kerns is rated as a Distinguished provider by MediFind in the treatment of Subacute Combined Degeneration. His top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Non-Hodgkin Lymphoma, and Pleuropulmonary Blastoma. Dr. Kerns is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Schleicher's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 54 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile